glp 1 prior authorization criteria Indications for GLP-1/GIP RA Summary Sheet and Beyond! The Medicare GLP-1 Bridge Begins

Keywords: Obesity, Diabetes, GLP-1 receptor agonist, Depression, Binge-eating disorder, Qualitative Introduction Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of drugs developed initially for treatment of type 2 diabetes (T2D) and then obesity, by mimicking the incretin effect which includes glucose-dependent increased insulin secretion and improved glycaemic control, and inducing weight loss in a dose-dependent manner [1]

Schelke L, Harris S, Cartier H, et al

2

Take someone like Marcus, a 38-year-old recreational runner in San Jose

Diabetes 59 (11), 26972707

the dorsal-vagal-complex (DVC), which contains the area postrema and the nucleus tractus solitarius [28]